Profile data is unavailable for this security.
About the company
J.B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. The Company specializes in gastroenterology, hypertension and dermatology. It is also focused on other therapeutic categories like nephrology, respiratory, virology, diabetes, and nicotine replacement therapy (NRT). The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredients (APIs). Its brands include Nicardia, Cilacar, Rantac, Metrogyl, and Cilacar-T. It specializes in manufacturing of medicated and herbal lozenges. All its lozenges (herbal, medicated and soft-centered) can be made in sugar and sugar-free options. It has implemented osmotic-controlled release oral drug delivery system (OROS) technology. It maintains a direct presence in Russia and South Africa, along with distributor relationships in the United States and various markets throughout Asia, Africa, and Latin America.
- Revenue in INR (TTM)35.92bn
- Net income in INR5.87bn
- Incorporated1976
- Employees5.31k
- LocationJ B Chemicals and Pharmaceuticals LtdCnergy It Park, Appa Saheb Marathe MargMUMBAI 400025IndiaIND
- Phone+91 2 224395200
- Fax+91 2 224395500
- Websitehttps://jbpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi India Ltd | 23.83bn | 4.30bn | 164.60bn | 2.17k | 38.30 | 24.04 | 35.17 | 6.91 | 186.62 | 229.86 | 1,034.61 | 297.26 | 1.67 | 2.73 | 15.60 | 10,960,440.00 | 30.08 | 22.42 | 57.55 | 30.21 | 55.95 | 55.52 | 18.04 | 21.03 | 0.8140 | 435.86 | 0.0313 | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Astrazeneca Pharma India Ltd | 13.88bn | 958.59m | 167.89bn | 940.00 | 175.14 | -- | 151.37 | 12.10 | 38.34 | 38.34 | 555.18 | -- | -- | -- | -- | 14,761,520.00 | -- | 11.78 | -- | 19.62 | 48.51 | 54.64 | 6.91 | 10.27 | -- | 121.25 | -- | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
| Jubilant Pharmova Ltd | 68.48bn | 5.53bn | 189.82bn | 995.00 | 34.38 | -- | 20.38 | 2.77 | 34.86 | 34.86 | 432.21 | -- | -- | -- | -- | 68,821,100.00 | -- | 2.96 | -- | 3.55 | 68.13 | 68.47 | 8.01 | 5.13 | -- | 2.34 | -- | 24.73 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
| Eris Lifesciences Ltd | 22.62bn | 3.80bn | 190.11bn | 3.08k | 50.05 | -- | 31.14 | 8.40 | 27.91 | 27.91 | 166.06 | -- | -- | -- | -- | 7,344,939.00 | -- | 13.42 | -- | 16.80 | 78.68 | 79.98 | 17.36 | 24.96 | -- | 4.20 | -- | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
| Concord Biotech Ltd | 10.38bn | 3.13bn | 228.23bn | 1.38k | 72.89 | -- | 62.20 | 21.99 | 29.93 | 29.93 | 99.19 | -- | -- | -- | -- | 7,537,496.00 | -- | -- | -- | -- | 77.16 | -- | 30.18 | -- | -- | 115.93 | -- | -- | 19.20 | -- | 28.33 | -- | -- | -- |
| Alembic Pharmaceuticals Ltd | 63.04bn | 6.30bn | 233.77bn | 14.86k | 37.12 | -- | 25.82 | 3.71 | 32.04 | 32.04 | 320.63 | -- | -- | -- | -- | 4,242,974.00 | -- | 10.72 | -- | 14.25 | 73.10 | 65.98 | 9.99 | 12.47 | -- | 12.52 | -- | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
| Laurus Labs Ltd | 50.54bn | 1.48bn | 261.71bn | 6.01k | 176.97 | -- | 47.35 | 5.18 | 2.74 | 2.74 | 93.40 | -- | -- | -- | -- | 8,413,434.00 | -- | 10.13 | -- | 16.47 | 52.80 | 47.63 | 3.01 | 12.83 | -- | 2.04 | -- | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| Pfizer Ltd | 22.25bn | 6.09bn | 266.72bn | 1.72k | 43.83 | -- | 39.82 | 11.99 | 133.01 | 133.01 | 486.27 | -- | -- | -- | -- | 12,926,610.00 | -- | 14.22 | -- | 17.71 | 65.06 | 61.37 | 27.35 | 24.05 | -- | 43.74 | -- | 82.67 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
| Natco Pharma Ltd. | 42.21bn | 16.37bn | 276.38bn | 4.02k | 16.89 | -- | 15.15 | 6.55 | 91.37 | 91.37 | 235.68 | -- | -- | -- | -- | 10,510,210.00 | -- | 12.33 | -- | 14.25 | 83.40 | 73.05 | 38.77 | 25.16 | -- | 91.13 | -- | 18.96 | 47.72 | 13.81 | 94.09 | 16.59 | -5.76 | 14.87 |
| J B Chemicals and Pharmaceuticals Ltd | 35.92bn | 5.87bn | 288.42bn | 5.31k | 50.21 | -- | 39.25 | 8.03 | 36.99 | 36.99 | 226.16 | -- | -- | -- | -- | 6,764,044.00 | -- | 15.77 | -- | 18.89 | 66.27 | 61.18 | 16.34 | 16.06 | -- | 21.04 | -- | 33.08 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
| Emcure Pharmaceuticals Ltd | -100.00bn | -100.00bn | 288.68bn | 11.15k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.14 | -- | 13.93 | -- | 59.29 | -- | 7.81 | -- | -- | -- | 0.00 | 11.23 | 7.14 | -6.36 | 21.35 | -5.93 | -- |
| Suven Pharmaceuticals Ltd | 9.34bn | 2.40bn | 291.41bn | 1.05k | 121.06 | -- | 98.48 | 31.18 | 9.46 | 9.46 | 36.75 | -- | -- | -- | -- | 8,883,019.00 | -- | 23.17 | -- | 26.20 | 56.59 | 58.85 | 25.73 | 33.21 | -- | 33.74 | -- | 18.63 | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
| Piramal Pharma Ltd | 83.73bn | 277.60m | 302.68bn | 6.72k | 1,088.60 | -- | 38.84 | 3.61 | 0.2107 | 0.2107 | 64.75 | -- | -- | -- | -- | 12,462,350.00 | -- | -- | -- | -- | 64.15 | -- | 0.3315 | -- | -- | 7.12 | -- | -- | 15.39 | -- | 109.56 | -- | -- | -- |
| Gland Pharma Ltd | 58.58bn | 7.22bn | 303.39bn | 4.22k | 42.01 | -- | 27.75 | 5.18 | 43.83 | 43.83 | 355.57 | -- | -- | -- | -- | 13,890,770.00 | -- | 13.23 | -- | 14.56 | 61.00 | 55.58 | 12.33 | 22.92 | -- | 34.66 | -- | 7.26 | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
| IPCA Laboratories Ltd | 82.12bn | 5.77bn | 367.03bn | 17.34k | 63.63 | -- | 38.68 | 4.47 | 22.74 | 22.74 | 323.71 | -- | -- | -- | -- | 4,737,502.00 | -- | 10.33 | -- | 13.52 | 67.08 | 59.16 | 6.84 | 12.25 | -- | 15.41 | -- | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
| Ajanta Pharma Ltd | 43.33bn | 8.54bn | 389.87bn | 7.84k | 46.04 | -- | 39.38 | 9.00 | 67.79 | 67.79 | 343.97 | -- | -- | -- | -- | 5,523,445.00 | -- | 16.61 | -- | 20.47 | 75.01 | 73.22 | 19.71 | 19.31 | -- | -- | -- | 31.20 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
Data as of Sep 19 2024. Currency figures normalised to J B Chemicals and Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
17.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Aug 2024 | 4.68m | 3.01% |
| Axis Asset Management Co. Ltd.as of 31 Aug 2024 | 4.37m | 2.82% |
| Abrdn Asia Ltd.as of 12 Sep 2024 | 3.69m | 2.37% |
| The Vanguard Group, Inc.as of 04 Sep 2024 | 2.67m | 1.72% |
| Norges Bank Investment Managementas of 31 Mar 2024 | 2.47m | 1.59% |
| Kotak Mahindra Asset Management Co. Ltd.as of 31 Aug 2024 | 2.46m | 1.58% |
| Canara Robeco Asset Management Co. Ltd.as of 31 Aug 2024 | 1.92m | 1.24% |
| Invesco Asset Management (India) Pvt Ltd.as of 31 Aug 2024 | 1.86m | 1.20% |
| Kotak Mahindra Life Insurance Co., Ltd.as of 31 Mar 2024 | 1.55m | 1.00% |
| Franklin Templeton Asset Management (India) Pvt Ltd.as of 30 Aug 2024 | 1.45m | 0.93% |
More ▼
Data from 30 Jun 2024 - 12 Sep 2024Source: FactSet Research Systems Inc.
